tradmap

NUWE Nuwellis, Inc.

$5.20 -2.62%

Data as of close

Healthcare · Electromedical & Electrotherapeutic Apparatus

Nuwellis, Inc. (NUWE) is a healthcare company in the Electromedical & Electrotherapeutic Apparatus industry, with a market capitalization of $2 million. Shares last traded at $5.20, 99.7% below their 52-week high. Over the past year the stock is down 99.5%. Net profit margin is -125.6%, below the peer median of -10.0%. Revenue declined 5.4% year over year.

Market Cap
$2M
Shares Out
405,251.556
EPS (TTM)
$19393.20
P/E (TTM)*
—
P/S Ratio
0.23
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$1984.50
52-Week Low
$2.56
Volume (venue)
870
Avg Vol (3m, venue)
18,914.912

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+71.96%
1M
-16.51%
3M
-67.54%
6M
-98.46%
YTD
-99.05%
1Y
-99.47%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. NUWE split history →

Technicals

RSI (14)
44.15
SMA (50)
$6.53
SMA (200)
$236.98
Price vs SMA50
-20.33%
Price vs SMA200
-97.81%
ATR (14)
$1.01

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$9M
Net Income
-$11M
Gross Margin
69.7%
Operating Margin
-142.9%
Net Margin
-125.6%
Return on Equity
551.0%
Return on Assets
-124.1%
Current Ratio
1.97
Debt / Equity
-0.96
Revenue Growth (YoY)
-5.4%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$239.76 2026-08-13
Q1 2026 -$689.85 2026-05-15
Q4 2025 (derived) $20146.41 2026-03-11
FY 2025 -$7997.85 2026-03-11
Q3 2025 $176.40 2025-11-12
Q2 2025 -$19207.71 2025-08-14

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Electromedical & Electrotherapeutic Apparatus peers

NUWE vs 14 industry peers (Electromedical & Electrotherapeutic Apparatus), by market cap. Data as of close

P/S vs peers
0.23 / 2.65 med
-91% discount
Net margin vs peers
-125.6% / -10.0% med
below median
1–14 of 14
MDTMedtronic$127.0B24.283.3813.9%+2.86%
LIVNLivanova Plc$4.4B23.443.0012.8%+1.58%
ITGRInteger Holdings Corp$4.3B41.502.365.7%-0.02%
AXGNAxogen, Inc.$3.0B—11.16-12.0%+0.97%
TMDXTransmedics Group, Inc.$2.3B15.213.4522.7%+1.05%
CNMDConmed Corp$1.4B29.481.013.4%+5.20%
CBLLCeribell, Inc.$1.0B—10.15-64.7%+1.51%
INMDInmode Ltd.$867M9.242.3425.3%+3.56%
CVCapsoVision, Inc$337M———-1.32%
ELMDElectromed, Inc.$224M19.853.0415.3%-0.28%
FOCLEDAP TMS SA$161M—2.29-41.5%+2.26%
VANIVivani Medical, Inc.$99M—207.94—+0.00%
STXSStereotaxis, Inc.$88M—2.93-74.2%+2.76%
NRXSNeuraxis, INC$84M———-6.91%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.